DIAGNOSIS OF LEUKEMIA (CML) ONCOGENE (C-ABL) EXPRESSION

该项目的目的是将最新进展的成果应用于 分子生物学，特别是细胞癌基因的分子克隆， 癌基因相关肽的合成和原位染色体 杂交用于诊断、评估和监测人类 白血病--特别是慢性粒细胞白血病（CML）。 小说8 Kb RNA与转化细胞的正常细胞同源物杂交， 已在患者中检测到Abelson小鼠白血病病毒（c-abl）基因 CML和t（9，22）易位（Ph'染色体）。 它不存在 无t（9，22）的CML或其他白血病（罕见例外）。 我们 将分析慢性粒细胞白血病和相关骨髓增生性疾病患者 (Ph“阴性CML）。 目标是定义 更准确地说，Ph阴性白血病和相关c-abl表达 疾病阶段和对治疗的反应。 这些RNA研究将是 辅以c-abl相关患者的分析， 使用V-ABL探针的染色体杂交。 这些研究将使 CML和相关人类白血病的更精确（分子）定义。 （六）

The object of this project is to apply results of recent advances in molecular biology, specifically molecular cloning of cellular oncogenes, synthesis of oncogene related peptides, and in situ chromosome hybridization to the diagnosis, evaluation, and monitoring of human leukemias--specifically to chronic myelogenous leukemia (CML). A novel 8 Kb RNA hybridizing with the normal, cellular homologue of the transforming gene of Abelson murine leukemia virus (c-abl) has been detected in patients with CML and the t(9,22) translocation (Ph' chromosome). It is not present in CML without the t(9,22) or other leukemias with rare exceptions. We will analyze patients with CML and related myeloproliferative disorders (Ph' negative CML) for this novel c-abl RNA. The objective is to define more precisely the Ph' negative leukemia and to correlate c-abl expression with disease phase and response to therapy. These RNA studies are to be complemented with analysis of c-abl related patients and by in situ chromosome hybridization using a v-abl probe. These studies will allow a more precise (molecular) definition of CML and related human leukemias. (6)